Clinical Trial Update: Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the safety and preliminary activity of the combination temsirolimus and brentuximab vedotin in adults with relapsed or refractory Hodgk…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)
• Temsirolimus (temsirolimus)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Adult Hodgkin Lymphoma | Phase 1 | Status: COMPLETED